Compare SWBI & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | BBOT |
|---|---|---|
| Founded | 1852 | 2016 |
| Country | United States | United States |
| Employees | N/A | 106 |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 651.8M | 605.6M |
| IPO Year | 2000 | N/A |
| Metric | SWBI | BBOT |
|---|---|---|
| Price | $15.63 | $7.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $14.00 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 953.4K | 389.3K |
| Earning Date | 06-17-2026 | 05-26-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ 36.67 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $523,845,000.00 | N/A |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | $39.32 | ★ N/A |
| Revenue Growth | ★ 10.36 | N/A |
| 52 Week Low | $7.73 | $7.00 |
| 52 Week High | $17.56 | $14.87 |
| Indicator | SWBI | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 45.79 |
| Support Level | $13.83 | $7.00 |
| Resistance Level | N/A | $8.10 |
| Average True Range (ATR) | 0.85 | 0.50 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 52.50 | 55.95 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.